<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158243">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02119793</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL015</org_study_id>
    <nct_id>NCT02119793</nct_id>
  </id_info>
  <brief_title>Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE® Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is purposed to evaluate the long-term efficacy and safety of repeat treatment of
      YVOIRE® contour injected into the anteromedial malar region in subjects who have completed
      the LG-HACL014 study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) score</measure>
    <time_frame>2, 26, and 52 weeks after repeat treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean of MFAS score as assessed by the independent blinded rater</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) score</measure>
    <time_frame>2, 26, and 52 weeks after repeat treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes of MFAS score as assessed by the independent blinded rater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) Responder rate</measure>
    <time_frame>2, 26, and 52 weeks after repeat treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>MFAS Responder (at least a one-point improvement on the MFAS) rate as assessed by the independent blinded rater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) score</measure>
    <time_frame>2, 26, and 52 weeks after repeat treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean of GAIS score as assessed by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) Responder rate</measure>
    <time_frame>2, 26, and 52 weeks after repeat treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>GAIS Responder (at least a one-point improvement on the GAIS) rate as assessed by subject</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region Who Have Completed the LG-HACL014 Study</condition>
  <arm_group>
    <arm_group_label>YVOIRE® contour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE® contour</intervention_name>
    <description>YVOIRE® contour injection into the anteromedial malar region</description>
    <arm_group_label>YVOIRE® contour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects who have completed the LG-HACL014 study

          -  Have anteromedial malar region volume loss at least a one-point worse on the MFAS
             compared with 2 weeks after treatment in the LG-HACL014 study

          -  Accept the obligation not to receive any other mid facial procedures or treatments
             during the study

          -  Signed informed consent

          -  Those who fall under one of the following 3 cases

               1. Males or females who are surgically sterile

               2. Post-Menopausal females who are above 45 years of age and 2 years after the last
                  menstruation

               3. Fertile premenopausal females or males without having a surgical sterilization,
                  who have agreed to use at least two contraception methods (one of the barrier
                  methods must be included) for up to 14 days after the repeat treatment of the
                  investigational device to avoid pregnancy

        Exclusion Criteria:

          -  Have a history of hypertrophic scars or keloids

          -  Other criteria as identified in the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yun-Ae Eom</last_name>
    <phone>82-2-6924-3157</phone>
    <email>yaeom@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seo</last_name>
      <email>doctorseo@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
